Clinical Study

A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting

Table 1

Clinical characteristics.

0.3 mg0.45 mg0.6 mg value
( = 17)( = 15)( = 18)

Male8 (53.3%)12 (80.0%)13 (72.2%)0.157
Age (year)58.94 ± 9.7461.64 ± 7.7657.72 ± 10.130.547
Weight (kg)63.82 ± 11.8362.94 ± 10.3461.82 ± 9.070.385
Height (cm)162.72 ± 4.92164.31 ± 7.67163.62 ± 7.550.885
BSA (m2)1.69 ± 0.181.70 ± 0.161.67 ± 0.180.923
Colon cancer
 Stage III12 (71%)12 (80%)14 (78%)0.895
 Stage IV5 (29%)3 (20%)4 (22%)
Use of rescue antiemetic3 (17.6%)5 (33.3%)3 (16.7%)0.810

Data are presented as mean ± standard deviation.
BSA, body surface area